Chanc Orzell

Abstract Broadly neutralizing antibodies (bnAbs) are a promising tool for HIV prevention and treatment. Here we conducted a first-in-human, phase 1 trial of the bispecific 10E8.4/iMab antibody, which consists of a 10E8.4 arm binding the HIV-1 envelope glycoprotein membrane-proximal external region and an ibalizumab (iMab) arm binding the human CD4 molecule. 10E8.4/iMab was administered intravenously (IV) or subcutaneously (SC).

Apple cider, pumpkins, falling leaves and … ticks? For the Vermont Agency of Agriculture, Food & Markets’ environmental surveillance program director Patti Casey and vector management coordinator Eliza Doncaster, the end of summer means it’s time to head out into the field to look for the creepy crawlies most of us are doing our best to avoid. Surveying ticks in Vermont is in its seventh year.